Related Experiment Video
Updated: Dec 20, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Aortic Insufficiency During HeartMate 3 Left Ventricular Assist Device Support
Teruhiko Imamura1, Nikhil Narang2, Gene Kim3
1(1)Department of Medicine, University of Chicago Medical Center, Chicago, Illinois; Second Department of Medicine, University of Toyama, Toyama, Japan.
Background:
Aortic insufficiency (AI) is associated with morbidity and mortality in patients with continuous-flow left ventricular assist devices (LVADs), whereas its impact on the HeartMate 3 LVAD cohorts remains uninvestigated. We aimed to investigate the clinical impact of AI on patients with HeartMate 3 LVADs.
Methods And Results:
Consecutive 61 patients (median age 54 years; 67% male) implanted with HeartMate 3 LVAD between 2015 and 2019 were enrolled and underwent echocardiography at 3 months after LVAD implantation. AI severity was quantified by the novel Doppler echocardiographic method obtained at the outflow cannula and the calculated regurgitation fraction of 30% or greater (moderate or greater) was defined as significant. At 3 months after implant, 12 patients (20%) had significant AI. They had a higher incidence of death or heart failure readmissions compared with those without significant AI during a 1-year observational period (70% vs 24%, P = .003) with an adjusted hazard ratio of 2.76 (95% confidence interval 1.03-7.88).
Conclusions:
In patients with HeartMate 3 LVAD support, significant AI remains both prevalent and a clinically significant downstream complication.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Cardiac Catheterization III: Left Heart Catheterization
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mitral Stenosis III: Medical Management
Cardiomyopathy V: Interprofessional Care
Mitral Stenosis I: Introduction

